Phaseline

Companies › PRG Science & Technology

PRG Science & Technology: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 1; Neurology, Metabolic and endocrine; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Progerinin–Phase 2Hutchinson-Gilford Progeria Syndrome; Werner SyndromeDec 2027
Amisodin–Phase 1Amyotrophic Lateral Sclerosis–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06775041ProgerininPhase 2Hutchinson-Gilford Progeria SyndromeMetabolic and endocrineMar 2026
NCT07221240AmisodinPhase 1Amyotrophic Lateral SclerosisNeurologyMay 2026
NCT05847179ProgerininPhase 2Werner SyndromeMetabolic and endocrineDec 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Urovant Sciences Corxel Pharmaceuticals Shenzhen Wingor Biotechnology NeuroBiogen Beijing Suncadia Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.